Viridian Metals Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 94
- Market Cap
- $956.7M
- Introduction
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Buy Rating Affirmed for Viking Therapeutics on Promising Clinical Trials and Strategic Focus
Leerink Partners analyst Thomas Smith reiterates Buy rating on VKTX stock, citing promising clinical trial results of VK-0214 for X-ALD and upcoming data from VK-2735 obesity program.
Viridian announces positive topline data from phase 3 THRIVE trial evaluating veligrotug in active thyroid eye disease
Viridian Therapeutics reports positive phase 3 THRIVE trial data for veligrotug in active thyroid eye disease, showing significant improvements across key endpoints at 15 weeks. Veligrotug, an anti-IGF-1R antibody, demonstrated a 70% proptosis responder rate and 67% overall responder rate, compared to 5% with placebo. The drug was well-tolerated with a low discontinuation rate and no serious AEs reported. THRIVE-2 for chronic TED is ongoing, with BLA submission planned for 2025.
Viridian Therapeutics' stock jumps after Phase III trial met all endpoints
Viridian Therapeutics' veligrotug met all primary and secondary endpoints in Phase III THRIVE trial for thyroid eye disease (TED), showing significant improvements in signs and symptoms. The treatment group had a 70% proptosis responder rate and 54% complete resolution of diplopia, compared to 5% and 12% in the placebo group, respectively. Veligrotug was generally well-tolerated, with no treatment-related serious adverse events. The company's stock price rose by 32% following the announcement.
Related Clinical Trials:
Veligrotug for treatment of thyroid eye disease meets endpoints in phase 3 trial
Veligrotug, an anti-insulin-like growth factor-1 receptor antibody, met all primary and secondary endpoints in the phase 3 THRIVE trial for treating active thyroid eye disease, showing significant improvement in symptoms and a high responder rate with mild adverse events.
Thyroid Eye Disease Treatment Shows Positive Results in Phase 3 Trial
Veligrotug, an anti-IGF-1R antibody, showed positive results in a phase 3 trial for active thyroid eye disease (TED), meeting primary and secondary endpoints. The therapy demonstrated substantial improvements in proptosis, clinical activity score, and diplopia after five infusions, with a rapid onset of action and generally well-tolerated side effects. Viridian Therapeutics plans to submit a biologics license application for veligrotug by the second half of 2025.
B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study
B.Riley raises Viridian Therapeutics' price target to $22.00 following positive Phase III THRIVE study results for VRDN-001 (veligrotug), projecting $500-$700 million in annual sales. Viridian also initiates $150 million stock offering and reports $571.4 million in cash reserves. Analysts predict VRDN-001 could capture 25-35% of Tepezza's market share.
Five biotech news stories you need to read today
Roivant acquires mosliciguat from Bayer for pulmonary hypertension; Viridian's thyroid eye disease treatment succeeds in Phase 3; Verily alums launch Highlander Health for clinical research optimization; House passes BIOSECURE Act restricting business with Chinese biotechs; Candid Therapeutics raises $370M for bispecific antibody therapies; Merck's Keytruda faces potential competition from Akeso's ivonescimab; Penn's gene therapy ATSN-101 shows promise for rare blindness.
Acelyrin shifts from main drug, lays off staff
Acelyrin shifts focus from izokibep to lonigutamab for thyroid eye disease, suspending further investments in izokibep despite positive trial results. The company cuts 43 jobs, aiming to extend cash runway to 2027 for lonigutamab's Phase 3 trials, amidst strategic restructuring.
Acelyrin eye drug heads to late-stage testing after trial win
Acelyrin plans late-stage testing for lonigutamab, a drug for thyroid eye disease, after positive Phase 2b/3 trial results. The drug showed clinically meaningful responses and was well-tolerated. Competing with Tepezza, lonigutamab offers a quicker, subcutaneous injection. Acelyrin's shares rose following the announcement.
© Copyright 2025. All Rights Reserved by MedPath